Aktie A2DKQS NEUROTROPE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Neurotrope, Inc.

Aktien

A2DKQS

US64129T2078

NTRP

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.
NEUROTROPE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
NEUROTROPE, INC. : Other Events (form 8-K)
NEUROTROPE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease
NEUROTROPE, INC. : Other Events (form 8-K)
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
NEUROTROPE, INC. : Other Events (form 8-K)
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Neurotrope : Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute Trial for Childhood Leukemia
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1
NEUROTROPE, INC. : Regulation FD Disclosure, Other Events (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DKQS Aktie
  4. Nachrichten Neurotrope, Inc.
  5. Andere Sprachen